
Oculis' Phase 3 trials for OCS-01 in diabetic macular edema fail primary vision improvement endpoint.
Oculis announced that its Phase 3 DIAMOND trials for OCS-01 eye drops in diabetic macular edema did not meet the primary endpoint of improved visual acuity after 52 weeks. However, the treatment showed significant and lasting reduction in retinal thi...

